Oncology And Technology With Carevive

Integrating patient-reported outcomes (PROs) into clinical practice is an increasingly promising strategy for improving patient engagement, symptom control, and clinical outcomes, including reducing avoidable hospitalizations and emergency room visits. Furthermore, recent data also shows that PRO-based proactive symptom monitoring may increase cancer patient survival. Now is the time to engage in discussions on practical applications of ePRO and finding the right balance of people, process, and technology. Recent advances in technology and survey methods may provide a solution to capturing PROs. There is evidence that the PRO approach can improve patient-clinician communication, ultimately improving a patient’s overall quality of life. An ePRO system can play a key role in clinical decision-making, as symptom management would improve and clinicians would be more aware of how a patient feels. PROs are finding a significant place in healthcare quality metrics, and PROs are sometimes thought to be more reliab

Carevive’s Dr. Carrie Stricker led an expert panel the ACCC 44th Annual Meeting and Cancer Center Business Summit in which perspectives were shared on a collaborative research initiative—designed to advance the science of patient engagement—using shared-decision making (SDM) to align clinician and patient understanding of care goals, while systematically enabling electronic capture of Patient-Reported Outcomes (PROs). Features talks from Ethan Basch, Brad Bott, and Nancy Paynter. To view the video please visit our wesbite: https://www.carevive.com/ondemand-patient-engagement-value-based-care/

In 2018, there will be an estimated 164,690 new cases of prostate cancer (PC) in the U.S. and approximately 29,430 patients will die of the disease, making it the third-leading cause of cancer death in men (American Cancer Society [ACS], 2018). The majority of men with PC are treated with curative intent (i.e., with radical prostatectomy or radiation therapy) with good outcomes, but a fraction of men with locoregional PC will develop progressive disease. Men who have initial PSA/biochemical recurrence after curative treatment are a heterogeneous group of individuals with good overall prognosis, including a median metastasis-free survival (MFS) >8 years and a median overall survival (OS) of >23 years (Rozet et al., 2016). Approximately 10%-20% of prostate cancer patients develop castration-resistant PC (CRPC) within approximately 5 years of follow-up. Decisions about clinical management (i.e., when to start treatment) are challenging because it is unclear which patients will have shorter versus longer surviva

Acute myeloid leukemia (AML) is a disease of older adults, with a median age of presentation of 67 years; only 5-10% of patients are alive at 5 years. Traditionally older patients have not received intensive induction chemotherapy to avoid toxicities, yet current research shows fit patients treated with intensive chemotherapy have better outcomes than patients with no treatment. The goal of this program is to close existing cancer clinician competency gaps regarding new data on investigational agents for AML along with evolving evidence-based guidelines and current understanding of treatment outcomes among older patients with AML. Hematology care teams will receive updates on current treatment treatments, the new data on investigational agents for AML, and how to make risk-based decisions among older patients with AML. Presenter Thomas W. LeBlanc, MD Associate Professor of Medicine Duke Cancer Institute Ashley Leak Bryant, PhD, RN-BC, OCN University North Carolina Lineberger Comprehensive Cancer Center